Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

BACKGROUND: Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. However, risk factors for cardiac toxicity remain unclear. Our objective was to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, John H., Lenihan, Daniel J., Phillips, Sharon E., Harrell, Shelton L., Cornell, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048104/
https://www.ncbi.nlm.nih.gov/pubmed/32154000
http://dx.doi.org/10.1186/s40959-017-0023-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048104/
https://www.ncbi.nlm.nih.gov/pubmed/32154000
http://dx.doi.org/10.1186/s40959-017-0023-9

Ejemplares similares